Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and
to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.